Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat

Francesco E. Pontieri, Giuseppe Conti, Alessandro Zocchi, Cesare Fieschi, Francesco Orzi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The [14C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kg). At the lower dose, WIN 55212-2 increased energy metabolism selectively in the accumbens shell. Conversely, the higher dose of the drug reduced glucose utilization in the hippocampal formation and ventromedial thalamic nucleus without affecting energy metabolism in the accumbens shell. These results may be useful to further understanding the addictive potentials of cannabinoid drugs.

Original languageEnglish
Pages (from-to)773-776
Number of pages4
JournalNeuropsychopharmacology
Volume21
Issue number6
DOIs
Publication statusPublished - Dec 1999

Fingerprint

Intravenous Administration
Energy Metabolism
Pharmaceutical Preparations
Cannabinoid Receptor Agonists
Glucose
Thalamic Nuclei
Cannabinoids
Deoxyglucose
Nucleus Accumbens
Hippocampus
Dopamine
Brain
Win 55212-2

Keywords

  • Cannabinoids
  • Deoxyglucose
  • Drug abuse
  • Hippocampus
  • Nucleus accumbens
  • Shell
  • WIN 55212-2

ASJC Scopus subject areas

  • Pharmacology

Cite this

Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat. / Pontieri, Francesco E.; Conti, Giuseppe; Zocchi, Alessandro; Fieschi, Cesare; Orzi, Francesco.

In: Neuropsychopharmacology, Vol. 21, No. 6, 12.1999, p. 773-776.

Research output: Contribution to journalArticle

Pontieri, Francesco E. ; Conti, Giuseppe ; Zocchi, Alessandro ; Fieschi, Cesare ; Orzi, Francesco. / Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat. In: Neuropsychopharmacology. 1999 ; Vol. 21, No. 6. pp. 773-776.
@article{258de53ba1ec46c5892d56c58c9a4c81,
title = "Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat",
abstract = "The [14C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kg). At the lower dose, WIN 55212-2 increased energy metabolism selectively in the accumbens shell. Conversely, the higher dose of the drug reduced glucose utilization in the hippocampal formation and ventromedial thalamic nucleus without affecting energy metabolism in the accumbens shell. These results may be useful to further understanding the addictive potentials of cannabinoid drugs.",
keywords = "Cannabinoids, Deoxyglucose, Drug abuse, Hippocampus, Nucleus accumbens, Shell, WIN 55212-2",
author = "Pontieri, {Francesco E.} and Giuseppe Conti and Alessandro Zocchi and Cesare Fieschi and Francesco Orzi",
year = "1999",
month = "12",
doi = "10.1016/S0893-133X(99)00064-0",
language = "English",
volume = "21",
pages = "773--776",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Metabolic mapping of the effects of win 55212-2 intravenous administration in the rat

AU - Pontieri, Francesco E.

AU - Conti, Giuseppe

AU - Zocchi, Alessandro

AU - Fieschi, Cesare

AU - Orzi, Francesco

PY - 1999/12

Y1 - 1999/12

N2 - The [14C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kg). At the lower dose, WIN 55212-2 increased energy metabolism selectively in the accumbens shell. Conversely, the higher dose of the drug reduced glucose utilization in the hippocampal formation and ventromedial thalamic nucleus without affecting energy metabolism in the accumbens shell. These results may be useful to further understanding the addictive potentials of cannabinoid drugs.

AB - The [14C]2-deoxyglucose method was applied to measure the effects of the synthetic cannabinoid agonist WIN 55212-2 intravenous administration on glucose utilization in the rat brain. Two doses of the drug, that have been reported previously to increase extracellular dopamine concentrations in the shell of the nucleus accumbens, were used (0.15-0.30 mg/kg). At the lower dose, WIN 55212-2 increased energy metabolism selectively in the accumbens shell. Conversely, the higher dose of the drug reduced glucose utilization in the hippocampal formation and ventromedial thalamic nucleus without affecting energy metabolism in the accumbens shell. These results may be useful to further understanding the addictive potentials of cannabinoid drugs.

KW - Cannabinoids

KW - Deoxyglucose

KW - Drug abuse

KW - Hippocampus

KW - Nucleus accumbens

KW - Shell

KW - WIN 55212-2

UR - http://www.scopus.com/inward/record.url?scp=0032793378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032793378&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(99)00064-0

DO - 10.1016/S0893-133X(99)00064-0

M3 - Article

C2 - 10633483

AN - SCOPUS:0032793378

VL - 21

SP - 773

EP - 776

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -